The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
The entire integration and transition of the brands is expected to be completed by March 2022
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
